Study to Evaluate the Fecal Microbiota Transplantation (FMT) in the Treatment of Ulcerative Colitis

Inclusion Criteria:

* Diagnosis of active UC defined on clinical grounds (Partial Mayo score ≥ 3 with each subscore \>1)
* Sexually active male and female subjects of childbearing potential must agree to use an effective method of birth control during the study.
* Female subjects of childbearing potential must have a negative urine Qualitative Human Chorionic Gonadotropin(HCG)pregnancy test at enrolment and on the Week 1, Day 1 of the Treatment prior to administration of study drug.
* Willing and able to sign an informed consent form and attend all study-related clinic visits, assessments, and follow-up phone calls.
* Subject has an attending physician who will provide the non-FMT care.

Exclusion Criteria:

* Subjects with sever UC (Mayo score of \>7)
* Unable to take retention enema or multiple capsules orally.
* Females who are pregnant, breastfeeding, or planning to become pregnant during the study.
* Receipt of systemic non-topical antibiotics within 14 days of treatment day 1.
* Positive results for active HIV, Hepatitis B, or Hepatitis C infections.
* History of recurrent Clostridium difficile infection or FMT in the past 6-months.
* History of other active gastrointestinal conditions such as irritable bowel syndrome, microscopic colitis, celiac disease, short gut syndrome, colostomy, colectomy, gastrointestinal fistulae or strictures, chronic parasitic infections, diverticulitis etc.
* Known history of bile acid diarrhea
* Compromised immune system (e.g. primary immune disorders or clinical immunosuppression due to a medical condition or medication e.g. taking oral prednisone \>20 mg a day or prednisone-equivalent)
* History of active cancer and/or ongoing chemotherapy (superficial non-metastatic cancers and maintenance chemotherapy are permitted).
* History of use of an investigational drug within 90 days prior to the screening visit.
* History of significant uncontrolled systemic disease that in the opinion of the study investigator could interfere with study participation and/or objectives.
* Life expectancy of \< 1 year.
* In the opinion of investigator, subject for any reason, should be excluded from the study.
* Absolute neutrophil count (ANC) \< 500IU/mL